Society for Immunotherapy of Cancer (SITC) 38th Meeting
SITC 2023 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. The Annual Meeting consists of cutting-edge research presentations by experts in the field, with NanoString hosting a workshop on Friday, November 3.
NanoString is excited to launch the GeoMx® IO Proteome Atlas (IPA) at SITC 2023! Please celebrate the launch of GeoMx IPA on Friday, November 3 at 5:00-7:00 pm during our GeoMX IPA “Hoppy Hour” at NanoString Booth #213!
Along with the launch of GeoMx IPA, we are excited to be hosting Abcam Experts in our booth during lunch and poster sessions!
Finally, we are thrilled to have VisioPharm join us at the NanoString booth to demonstrate the latest in AI-driven Integrated workflows to analyze four-color fluorescent images generated by GeoMx® Digital Spatial Profiler and CosMx™ Spatial Molecular Imager.
Revolutionizing Immuno-oncology with Spatial Biology
Nov. 3, 12:15–1:15pm | Room 16 AB
NanoString’s Spatial Biology solutions provide unprecedented opportunities to understand how cells organize and regulate across the tissue landscape to drive disease progression and response to anti-cancer therapies. Join us to learn about The GeoMx®IO Proteome Atlas (IPA), the most comprehensive human spatial proteomics assay enabling spatial profiling of 570+ immuno-oncology (IO) relevant targets from FFPE (Formalin Fixed, Paraffin Embedded) tissue sections. Containing nearly all IHC-compatible antibodies from Abcam’s IO catalog. Hear from Dr. David Ting, Massachusetts General Hospital, and his use of spatial single slide spatial proteogenomics utilizing the GeoMx® Whole Transcriptome Atlas (WTA) in conjunction with GeoMx IPA for high-plex spatial multiomics of randomized pancreatic cancer immunotherapy clinical trial samples. Learn how spatial technologies can power your immunotherapy research, improve your understanding of cancer development, progression, and microenvironment interactions, enhance your biomarker discovery, and streamline your therapeutic development.
The CosMx™ SMI and decoder probes are not offered and/or delivered to the Federal Republic of Germany for use in the Federal Republic of Germany for the detection of cellular RNA, messenger RNA, microRNA, ribosomal RNA and any combinations thereof in a method used in fluorescence in situ hybridization for detecting a plurality of analytes in a sample without the consent of the President and Fellows of Harvard College (Harvard Corporation) as owner of the German part of EP 2 794 928 B1. The use for the detection of cellular RNA, messenger RNA, microRNA, ribosomal RNA and any combinations thereof is prohibited without the consent of the President and Fellows of Harvard College (Harvard Corporation).
The CosMx™ SMI and decoder probes are not offered and/or delivered to the following UPC member states* for use in these countries for the detection of RNA in a method used for the detection of a plurality of analytes in a cell or tissue sample without the consent of the President and Fellows of Harvard College (Harvard Corporation) as owner of the Unitary Patent EP 4 108 782 B1. The use for the detection of RNA is prohibited without the consent of the President and Fellows of Harvard College (Harvard Corporation).
* Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Slovenia, Sweden